My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Incyte Corporation - Common Stock (NQ:INCY)

104.15 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

18 19 20 21 22 23 24 25 Next >

BriaCell Therapeutics Attacks Cancer with Novel Off-the-Shelf Immunotherapies ↗

August 16, 2021

Photo by Chokniti Khongchum from Pexels In 2020, there were 2.3 million women globally diagnosed with breast cancer and 685,000 deaths, according to the World Health Organization...

Via Benzinga

Topics Death

Stocks That Hit 52-Week Lows On Tuesday ↗

August 10, 2021

Before 10 a.m. ET on Tuesday, 60 companies set new 52-week lows. Key Facts: PACCAR (NASDAQ:PCAR) was the biggest company by market cap to set a new 52-week low....

Via Benzinga

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO ↗

August 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (...

Via Benzinga

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗

August 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...

Via Benzinga

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗

August 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...

Via Benzinga

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts ↗

August 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...

Via Benzinga

Is the PD-(L)1 Party Over After Incyte's FDA Rejection? ↗

August 07, 2021

There's definitely already a crowded market for PD-1 and PD-L1 immunotherapies.

Via The Motley Fool

Incyte Corporation (INCY) Q2 2021 Earnings Call Transcript ↗

August 03, 2021

INCY earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

August 03, 2021

From Incyte

Via Business Wire

A Perspective On The Upcoming Calithera Cystic Fibrosis Read-Out ↗

August 02, 2021

Calithera is guiding for the market to expect what we believe will be a key data read-out in Q3 from its ongoing CB-280 study involving Cystic Fibrosis. A positive read-out here could see a significant...

Via Talk Markets

Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates ↗

August 02, 2021

The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi...

Via Benzinga

A Preview Of Incyte's Earnings ↗

August 02, 2021

Incyte (NASDAQ:INCY) will be releasing its next round of earnings this Tuesday, August 03. For all of the relevant information, here is your guide for Tuesday's Q2 earnings...

Via Benzinga

2 Stocks Under $100 You Can Buy and Hold Forever ↗

July 31, 2021

Drugmakers can be excellent long-term holdings.

Via The Motley Fool

Eli Lilly-Incyte's Rheumatoid Arthritis Drug Gets OK From FDA For Solo Use In Hospitalized COVID-19 Patients ↗

July 29, 2021

The FDA extended the Emergency Use Authorization (EUA) for Eli Lilly And Co's (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) rheumatoid...

Via Benzinga

FDA Strikes Off Incyte's Retifanlimab Application In Anal Cancer ↗

July 26, 2021

The

Via Benzinga

Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

July 23, 2021

From Incyte Corporation

Via Business Wire

Benchmark Upgrades Incyte After Stock Selloff ↗

July 20, 2021

The recent downturn in Incyte Corporation’s (NASDAQ:INCY...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021 ↗

July 20, 2021

Upgrades For Bank of Marin Bancorp (NASDAQ:

Via Benzinga

AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA ↗

July 16, 2021

AbbVie Inc (NYSE: ABBV) and Eli Lilly And Co (NYSE: LLY) will have to keep waiting for a chance for their JAK inhibitors in atopic dermatitis to see the market....

Via Benzinga

Incyte to Report Second Quarter Financial Results

July 15, 2021

From Incyte

Via Business Wire

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs ↗

July 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,...

Via Benzinga

Topics Product Recall

Incyte's Ruxolitinib Shows Better Outcomes Regardless Of Organs Affected In GvHD Patients ↗

July 15, 2021

Incyte Corporation (NASDAQ: INCY) has announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM...

Via Benzinga

Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease

July 14, 2021

From Incyte

Via Business Wire

BriaCell's Early-Stage Combination Study In Advanced Breast Cancer Starts Enrollment ↗

July 14, 2021

BriaCell Therapeutics Corp (NASDAQ: BCTX) has opened recruitment and enrollment of their collaborative clinical study with Incyte Corporation (NASDAQ:...

Via Benzinga

Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer ↗

July 09, 2021

The National Medical Products Administration (NMPA) of China has accepted for review Innovent Biologics Inc's (OTC: IVBIY) marketing application seeking...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates ↗

July 01, 2021

June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive...

Via Benzinga

EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters ↗

June 29, 2021

The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's (NYSE: LLY) rheumatoid arthritis drug for an initial...

Via Benzinga

FDA AdCom In Favor Of Delaying Incyte's Retifanlimab Approval In Anal Cancer ↗

June 25, 2021

Members of the Oncologic Drugs Advisory Committee

Via Benzinga

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

June 25, 2021

From Incyte

Via Business Wire

Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

June 24, 2021

From Incyte

Via Business Wire

< Previous 1 2

...

18 19 20 21 22 23 24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.